Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vitaxin applied molecular evolution.

K Mikecz1

  • 1Department of Orthopedic Surgery, Rush-Presbyterian-St Luke's Medical Center, 1653 West Congress Parkway, Chicago, IL 60612-3833, USA. kmikecz@rush.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary

Vitaxin, a novel antibody targeting alpha v beta 3 integrin, is being investigated for treating leiomyosarcoma and inflammatory conditions like rheumatoid arthritis. Further research is exploring its potential in other vitronectin-related diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteoglycan aggrecan conducting T cell activation and apoptosis in a murine model of rheumatoid arthritis.

BioMed research international·2014
Same author

Disease-promoting and -protective genomic loci on mouse chromosomes 3 and 19 control the incidence and severity of autoimmune arthritis.

Genes and immunity·2012
Same author

T cell receptor (TCR) signal strength controls arthritis severity in proteoglycan-specific TCR transgenic mice.

Clinical and experimental immunology·2012
Same author

Osteoarthritis-like damage of cartilage in the temporomandibular joints in mice with autoimmune inflammatory arthritis.

Osteoarthritis and cartilage·2011
Same author

Oral glucosamine modulates the response of the liver and lymphocytes of the mesenteric lymph nodes in a papain-induced model of joint damage and repair.

Osteoarthritis and cartilage·2009
Same author

Congenic strains displaying similar clinical phenotype of arthritis represent different immunologic models of inflammation.

Genes and immunity·2008

Area of Science:

  • Oncology
  • Immunology
  • Rheumatology

Background:

  • Vitaxin is a humanized monoclonal antibody (mAb) derived from LM-609.
  • It specifically targets and blocks the integrin receptor, alpha v beta 3.
  • This integrin is implicated in various disease processes.

Purpose of the Study:

  • To evaluate Vitaxin as a potential therapeutic agent for leiomyosarcoma.
  • To assess Vitaxin's efficacy as an anti-inflammatory therapy for rheumatoid arthritis.
  • To explore Vitaxin and non-peptide inhibitors for other vitronectin-associated diseases.

Main Methods:

  • Phase II clinical trials for leiomyosarcoma treatment.
  • Phase I clinical trials for anti-inflammatory and rheumatoid arthritis therapy.
  • Evaluation of Vitaxin and non-peptide compounds in preclinical models.

Main Results:

  • Vitaxin is currently in Phase II trials for leiomyosarcoma.
  • Phase I trials are investigating its anti-inflammatory and rheumatoid arthritis potential.
  • Ongoing studies explore applications in arthritis, psoriasis, and other inflammatory diseases.

Conclusions:

  • Vitaxin shows promise as a targeted therapy for leiomyosarcoma.
  • Its anti-inflammatory properties warrant further investigation for autoimmune and inflammatory conditions.
  • Development is expanding to other diseases involving vitronectin.

Related Experiment Videos